Microarray-based understanding of normal and malignant plasma cells

Immunological Reviews

Volumn 210, Issue , 2006, Pages 86-104

  De Vos, John ^a,b,c   Hose, Dirk ^d   Rème, Thierry ^b   Tarte, Karin ^e   Moreaux, Jérôme ^a,b   Mahtouk, Karéne ^a,b   Jourdan, Michel ^b   Goldschmidt, Hartmut ^e   Rossi, Jean François ^a,c   Cremer, Friedrich W ^e   Klein, Bernard ^a,b,c,f  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; BORTEZOMIB; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; SELECTIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TRANSCRIPTION FACTOR;

APOPTOSIS; BIOLOGY; BONE CELL; CANCER CELL; CELL CYCLE; CELL INTERACTION; CELL POPULATION; CELLULAR DISTRIBUTION; CHROMOSOME ABERRATION; CLINICAL TRIAL; CLONING; CYTOGENETICS; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE DIFFERENTIATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL TECHNOLOGY; MEMORY CELL; METABOLISM; MICROARRAY ANALYSIS; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOLYSIS; PHENOTYPE; PLASMA CELL; PLASMA CELL DYSCRASIA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; REVIEW; SPERMATOGENESIS; STEM CELL TRANSPLANTATION;

B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAPROTEINEMIAS; PLASMA CELLS;

EID: 33645315222     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2006.00362.x     Document Type: Review

References (122)

1. Slifka MK Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998 10 252 258.
2. Tarte K Zhan F De Vos J Klein B Shaughnessy J Jr.. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003 102 592 600.
3. Piskurich JF Lin KI Lin Y Wang Y Ting JP Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol 2000 1 526 532.
4. Shapiro-Shelef M Lin KI McHeyzer-Williams LJ Liao J McHeyzer-Williams MG Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003 19 607 620.
5. Shaffer AL et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002 17 51 62.
6. Lin Y Wong K Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997 276 596 599.
7. Shaffer AL Yu X He Y Boldrick J Chan EP Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000 13 199 212.
8. Phan RT Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004 432 635 639.
9. Fujita N et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 2004 119 75 86.
10. Lin KI Angelin-Duclos C Kuo TC Calame K. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol 2002 22 4771 4780.
11. Muto A et al. Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3′ enhancer. EMBO J 1998 17 5734 5743.
12. Lin H Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature 1995 376 263 267.
13. Mittrucker HW et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997 275 540 543.
14. Corcoran LM et al. Differential requirement for OBF-1 during antibody-secreting cell differentiation. J Exp Med 2005 201 1385 1396.
15. Honma S et al. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature 2002 419 841 844.
16. Tarte K et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002 100 1113 1122.
17. Pellat-Deceunynck C Bataille R. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 2004 32 293 301.
18. Robillard N Pellat-Deceunynck C Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005 105 4845 4848.
19. Terstappen L Steen J Seger-Nolten MJ Loken MR. Identification and characterization of plasma cells in normal bone marrow by high resolution flow cytometry. 1990 9 1739 1747.
20. Mahmoud MS Ishikawa H Fujii R Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood 1998 92 3887 3897.
21. Medina F Segundo C Brieva JA. Purification of human tonsil plasma cells. pre-enrichment step by immunomagnetic selection of CD31 (+) cells. Cytometry 2000 39 231 234.
22. Zhan F et al. Molecular profiling newly diagnosed multiple myeloma. Blood 2001 98 733a.
23. Odendahl M et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005 105 1614 1621.
24. Kunkel EJ Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003 3 822 829.
25. Ma Q Jones D Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999 10 463 471.
26. Hargreaves DC et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001 194 45 56.
27. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999 286 2098 2102.
28. De Vos J et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001 98 771 780.
29. Wright G Tan B Rosenwald A Hurt EH Wiestner A Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003 100 9991 9996.
30. Kopf M et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994 368 339 342.
31. Suematsu S et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989 86 7547 7551.
32. Jego G Bataille R Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001 97 1817 1822.
33. Seidl S Kaufmann H Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003 4 557 564.
34. Logan CY Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004 20 781 810.
35. Han JH Choi SJ Kurihara N Koide M Oba Y Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001 97 3349 3353.
36. Claudio JO et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002 100 2175 2186.
37. Salzer U et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005 37 820 828.
38. Mackay F Schneider P Rennert P Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003 21 231 264.
39. O'Connor BP et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004 199 91 98.
40. Ng LG Mackay CR Mackay F. The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 2005 42 763 772.
41. Moreaux J et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005 106 1021 1030.
42. Ingold K et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005 201 1375 1383.
43. Costes V et al. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 1999 30 1405 1411.
44. Volpe CP et al. Proximal promoter of the murine syndecan-1 gene is not sufficient for the developmental pattern of syndecan expression in B lineage cells. Am J Hematol 2001 67 20 26.
45. Sun RX et al. Large scale and clinical grade purification of syndecan-1+ malignant plasma cells. J Immunol Methods 1997 205 73 79.
46. Bernfield M et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999 68 729 777.
47. Borset M Hjertner O Yaccoby S Epstein J Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 2000 96 2528 2536.
48. Lu Q et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 1999 398 723 728.
49. Katagiri M et al. Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts. J Biol Chem 2001 276 7376 7382.
50. Lu Q Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001 293 306 311.
51. Angelillo-Scherrer A et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001 7 215 221.
52. Lan Z et al. Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway. Blood 2000 95 633 638.
53. van Ginkel PR et al. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 2004 64 128 134.
54. Yoshida H Matsui T Yamamoto A Okada T Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001 107 881 891.
55. Reimold AM et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001 412 300 307.
56. Iwakoshi NN Lee AH Vallabhajosyula P Otipoby KL Rajewsky K Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 2003 4 321 329.
57. Shaffer AL et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004 21 81 93.
58. Lee AH Iwakoshi NN Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 2003 23 7448 7459.
59. Marciniak SJ et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004 18 3066 3077.
60. Bakkus MH Heirman C Van Riet I Van Camp B Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992 80 2326 2335.
61. Harousseau JL Moreau P Attal M Facon T Avet-Loiseau H. Stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol 2005 18 603 618.
62. Singhal S et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999 341 1565 1571.
63. Richardson PG et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003 348 2609 2617.
64. Cavo M et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005 106 35 39.
65. Kyle RA et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002 346 564 569.
66. Fonseca R et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004 64 1546 1558.
67. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol 2002 55 273 283.
68. Smadja NV Bastard C Brigaudeau C Leroux D Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001 98 2229 2238.
69. Smadja NV et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003 38 234 239.
70. Fonseca R et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003 102 2562 2567.
71. Wuilleme S et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 2005 19 275 278.
72. Cremer FW et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005 44 194 203.
73. Garand R Avet-Loiseau H Accard F Moreau P Harousseau JL Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003 17 2032 2035.
74. Moreau P et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002 100 1579 1583.
75. Gertz MA et al. Clinical implications of t (11;14(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005 106 2837 2840.
76. Bergsagel PL Chesi M Nardini E Brents LA Kirby SL Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996 93 13931 13936.
77. Kroger N et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004 103 4056 4061.
78. Drach J et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998 92 802 809.
79. Chang H Qi C Yi QL Reece D Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005 105 358 360.
80. Zhan F et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002 99 1745 1757.
81. Zhan F Tian E Bumm K Smith R Barlogie B Shaughnessy J Jr.. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003 101 1128 1140.
82. Harousseau JL Shaughnessy J Richardson P. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2004 237 256.
83. Chesi M Bergsagel PL Kuehl WM. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr Opin Hematol 2002 9 288 293.
84. Santra M Zhan F Tian E Barlogie B Shaughnessy J Jr.. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003 101 2374 2376.
85. Bergsagel PL Kuehl WM Zhan F Sawyer J Barlogie B Shaughnessy J Jr.. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005 106 296 303.
86. Hose D et al. A new molecular classification of multiple myeloma using gene expression profiling and fluorescence in situ hybridisation as predictor for event free survival. Blood 2004 104 [abstract 73].
87. Shaughnessy J et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I. interpretation in the context of global gene expression. Blood 2003 101 3849 3856.
88. Cremer FW et al. Multiple myeloma: global expression profiling indicates upregulation of the ribosomal machinery in hyperdiploid clones. Blood 2004 1004 [abstract 1421].
89. Greipp PR Katzmann JA ''Fallon WM Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. 1988 72 219 223.
90. Gu ZJ et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 2000 14 188 197.
91. Dankbar B et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000 95 2630 2636.
92. Vacca A et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999 93 3064 3073.
93. Uchiyama H Barut BA Mohrbacher AF Chauhan D Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993 82 3712 3720.
94. Hideshima T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002 277 16639 16647.
95. Yaccoby S et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004 64 2016 2023.
96. Hurt EM et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004 5 191 199.
97. Vande Broek I Asosingh K Vanderkerken K Straetmans N Van Camp B Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003 88 855 862.
98. Abe M et al. Role for macrophage inflammatory protein (MIP) -1alpha and MIP-1 beta in the development of osteolytic lesions in multiple myeloma. Blood 2002 100 2195 2202.
99. Van Riet I Vanderkerken K de Greef C Van Camp B. Homing behaviour of the malignant cell clone in multiple myeloma. Med Oncol 1998 15 154 164.
100. Vande Broek I et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004 18 976 982.
101. Klein B et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003 78 106 113.
102. Kawano M et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988 332 83 85.
103. Klein B et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989 73 517 526.
104. Portier M et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 1991 21 1759 1762.
105. Klein B et al. Survival and proliferation factors of human myeloma cells. In: Bergsagel PL Kuehl M, eds. Recent Advances in the Biology of Multiple Myeloma Totawa NJ: Humana Press 2003.
106. Mahtouk K et al. An inhibitor of the EGF receptor family blocks myeloma cell growt h factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004 103 1829 1837.
107. Moreaux J et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004 103 3148 3157.
108. Wang YD et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 2002 21 2584 2592.
109. Harris RC Chung E Coffey RJ. EGF receptor ligands. Exp Cell Res 2003 284 2 13.
110. Graus-Porta D Beerli RR Daly JM Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997 16 1647 1655.
111. Mahtouk K et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 2005 24 3512 3524.
112. Klein B et al. Identification of intercellular communication signals involved in multiple myeloma with microarrays. Haematologica/the hematology journal 2005 100.
113. Qiu Y Ravi L Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998 393 83 85.
114. Badache A Hynes NE. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 2001 61 383 391.
115. Walters DK French JD Arendt BK Jelinek DF. Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex. Oncogene 2003 22 3598 3607.
116. Albanell J Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets 2005 6 259 274.
117. Novak AJ et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004 103 689 694.
118. Tian E et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003 349 2483 2494.
119. Derksen PW et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004 101 6122 6127.
120. De Vos J et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002 21 6848 6857.
121. Krampera M et al. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood 2005 106 59 66.
122. Qin L et al. Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation. J Biol Chem 2005 280 3974 3981.